REVIEW ARTICLE

Endocrine disorders in patients with hereditary hemochromatosis

Katarzyna Banaszkiewicz¹, Katarzyna Sikorska¹, Krzysztof Sworczak²

¹ Department of Tropical Medicine and Epidemiology, Medical University of Gdańsk, Gdynia, Poland
² Department of Endocrinology and Internal Medicine, Medical University of Gdańsk, Poland

Abstract

Hereditary hemochromatosis (HH) is a rare genetic disorder, developing secondary to the accumulation of iron in tissues, which may lead to multiple organ failure. If untreated, it may result in liver cirrhosis or cardiomyopathy. The damage to the pancreas and the anterior pituitary, on the other hand, leads to a decreased production and secretion of hormones that are essential to life. Common symptoms of HH, that are distressing for patients, include joint pain, particularly involving hands and wrists, as well as the chronic fatigue syndrome. Iron overload affects the skeletal system, leading to osteoporosis. The pathological accumulation of iron in the anterior pituitary impairs the gonadotropin synthesis, resulting in reduced serum levels of testosterone in men and estrogens in women. This, however, contributes to lower bone mass. In vivo tests have also revealed that abnormal iron accumulation is related to an increased activity and number of osteoclasts, as well as the influence on the differentiation and activity of osteoblast-lineage cells. Based on a systematic review of literature, hereditary hemochromatosis (HH) will be presented as a chronic disease, affecting most of the endocrine glands.

Keywords: diabetes mellitus / Osteoporosis / endocrinology / iron overload / hemochromatosis

Citation


Introduction

HFE (human hemochromatosis protein)-associated hereditary hemochromatosis (HH) is an autosomal recessive genetic disorder. Among the Caucasian population, mutations of the HFE gene account for 60-96% of cases in which the symptoms of iron overload develop. Classic HH-Hereditary Hemochromatosis develops in homozygotic carriers of the C282Y mutation in the HFE gene – as a result of a point mutation in the nucle-
otide (845G>A), cysteine is substituted with tyrosine in the HFE protein. The prevalence of this mutation among the Caucasian population has been estimated at 3-10 cases per 1000 people, which means that HH is one of the most prevalent genetic metabolic diseases [1].

Other polymorphisms in the HFE gene (H63D – substitution of histidine with aspartic acid, S65C – substitution of serine with cysteine), which are frequently detected, do not cause such serious alterations within the spatial structure of the HFE protein and such dynamic symptoms of iron overload [2].

Most commonly, the first clinical manifestation of the disease involves symptoms of liver damage, which in most cases of untreated primary HH leads to liver cirrhosis with significant risk of hepatocarcinogenesis [3]. Iron deposition in other organs can also lead to: diabetes mellitus, cardiomyopathy, bone and joint pathology, hypopituitarism and easily noticeable (brow-nish) skin discoloration. Early diagnosis and treatment aimed at reducing the tissue iron concentration (e.g. bloodletting as a first-line therapy, iron chelation therapy) are of undeniable importance in preventing irreversible organ damage [4-7].

Any pathological changes in endocrine glands may develop secondary to pathological iron accumulation of a different etiology. In classic HH, these changes are usually diagnosed concomitantly with the main liver pathology. In juvenile hemochromatosis, which is a very rare disorder developing secondary to underlying mutations in the hepcidin gene or the hemojuvelin gene with rapidly progressive iron accumulation, hormonal imbalance manifests itself at a younger age in the form of severe endocrinological dysfunctions (Figure 1) [8].

A juvenile hemochromatosis type 2, a disease with severe symptoms of iron accumulation and an early onset, is diagnosed in patients with abnormal synthesis of hepcidin or hemojuvelin. It is a rare disease characterized by a dynamic cycle of iron deposition in tissues, quick depletion of liver’s compensating capacity for storing iron and development of symptoms associated with the failure of the heart muscle and endocrine glands. Mutations in the TFR2 (transferrin receptor 2 gene) encoding gene that cause the dys-

Figure 1. Clinical picture of hemochromatosis depending on mutation of genes encoding HFE, hepcidin (HAMP), hemojuvelin (HJV), transferrin 2 receptor (TFR2), ferroportin (FPN). Organ changes may concern: liver, heart, endocrine organs. Image modification from: Pietrangelo A.: Hereditary Hemochromatosis: Pathogenesis, Diagnosis and Treatment. Gastroenterology 2010; 139: 393-408
The authors suggested that the dysfunction of the adrenal gland with a decreased ACTH (adrenocorticotropic hormone) production, but also the dysfunction of the adrenal cortex demonstrated in ACTH stimulation tests [11]. Among few publications devoted to juvenile hemochromatosis, there is a case study from 2000, describing a patient with juvenile hemochromatosis, whose only endocrine disorder was isolated adrenal insufficiency without the presence of anti-adrenal antibodies. The authors suggested that the dysfunction of the adrenal glands in this patient is due to the advanced stage of iron overload in tissues [12]. In 2018 a clinical case was published in which the patient’s adrenal cortex was damaged in the course of hemochromatosis with homozygous H63D mutation, which was confirmed by endocrinological diagnostics and iron deposits in the adrenal MRI examination [13].

Adrenal insufficiency also develops secondary to the dysfunction of the pituitary gland. In the case of hemochromatosis, the increased deposition of iron in the cells of the pituitary gland may lead to a decreased secretion of tropic hormones [14]. The most common endocrine disorder in patients with hereditary hemochromatosis is hypogonadotropic hypogonadism, which causes low libido (26% of patients) and impotence in men (45% of men). Hypogonadism in patients with hemochromatosis is supposedly caused by both the dysfunction of the hypothalamic-pituitary axis and the destruction of Leydig cells [15].

Adrenal gland dysfunction

Hemochromatosis, along with sarcoidosis, amyloidosis and non-Hodgkin lymphomas, is listed as one of the causes of primary adrenal insufficiency, which supposedly develops due to the so-called infiltration of the glandular tissue. According to this hypothesis, excessive accumulation of iron may lead to adrenal damage due to oxidative stress, induced by high oxidation-reduction potential of iron [10].

Numerous data concerning the etiopathogenetic relationship between iron overload and endocrine disease are based on observations of patients with secondary hemochromatosis, e.g. patients diagnosed with thalassemia. Adrenal insufficiency affects 13-46% of such patients. Researchers confirmed the dysfunction of the pituitary gland with a decreased ACTH (adrenocorticotropic hormone) production, but also the dysfunction of the adrenal cortex demonstrated in ACTH stimulation tests [11].

Among few publications devoted to juvenile hemochromatosis, there is a case study from 2000, describing a patient with juvenile hemochromatosis, whose only endocrine disorder was isolated adrenal insufficiency without the presence of anti-adrenal antibodies. The authors suggested that the dysfunction of the adrenal glands in this patient is due to the advanced stage of iron overload in tissues [12]. In 2018 a clinical case was published in which the patient’s adrenal cortex was damaged in the course of hemochromatosis with homozygous H63D mutation, which was confirmed by endocrinological diagnostics and iron deposits in the adrenal MRI examination [13].

Adrenal insufficiency also develops secondary to the dysfunction of the pituitary gland. In the case of hemochromatosis, the increased deposition of iron in the cells of the pituitary gland may lead to a decreased secretion of tropic hormones [14]. The most common endocrine disorder in patients with hereditary hemochromatosis is hypogonadotropic hypogonadism, which causes low libido (26% of patients) and impotence in men (45% of men). Hypogonadism in patients with hemochromatosis is supposedly caused by both the dysfunction of the hypothalamic-pituitary axis and the destruction of Leydig cells [15].

Hypothyroidism

Hypothyroidism is another disorder that can occur among people with congenital hemochromatosis. Published data referring to the incidence of thyroid dysfunctions among patients diagnosed with congenital hemochromatosis are incoherent and inconclusive. In a 1983 study, Edwards and co-authors demonstrated an increased incidence of primary hypothyroidism in patients with congenital hemochromatosis, but more recent reports from 2004 do not confirm this. The explanation for the relatively low incidence of thyroid disease among patients with hereditary hemochromatosis may be the fact that pituitary glandular cells are more sensitive than thyroid cells to the damaging effects of iron deposits [16-17].

Hypogonadism and osteoporosis

Hypogonadism may lead to a decreased bone mass in men, which is a frequent finding in patients with HH. In a study from 2008 conducted on a group of 87 patients with hemochromatosis who were tested for reduced bone mineral density (BMD), it was found that 25% of them suffered from osteoporosis, and 41% from osteoarthritis. Moreover, it was stated that BMD was dependent on BMI (body mass index), alkaline phosphatase level, hypogonadism/menopause and the intensity of iron deposition in the liver. However, there was no correlation with liver cirrhosis. In a study from 2005 osteopenia was found in 30 out of 38 patients (78.9%), while osteoporosis in 13 out of 38 patients (34%). The decrease in BMD was greater in the femoral neck than in the lumbar region of the spine [18-19].

In vivo tests suggested that there is a relationship between excessive iron accumulation and an increase in the activity and number of osteoclasts. When analyzing the problem, it is also important to remember about the calcium and phosphate homeostasis, which is disturbed in patients with liver impairment. In chronic liver disease, 20-100% of patients develop the so-called hepatic osteodystrophy. It has also been confirmed that iron has a negative influence on bones. In vivo tests revealed that iron overload suppresses osteoblastic differentiation and activity, which is associated with increased apoptosis of osteoblasts [20]. Iron has also a negative impact on bones through BMP2 (Bone Morphogenetic Protein 2) and osteoblastogenesis. Study results from 2009 suggest that iron overload may contribute to the development of osteoporosis as a result of inhibited osteoblastic proliferation and differentiation [21].

In research from 2008, the HFE gene was mutated in rats causing excessive iron accumulation in the kidneys and liver. The research showed that there was a decrease in connections between cells in the trabecular bone of the femur. Recently, the results of the studies analyzing the influence of iron on the microarchitecture of bones have been published. It was found that animals with iron disorders have a reduced BFR
(bone formation rate), which suggests that iron has a direct influence on the percentage of active osteoblasts. Based on the bone mass analysis, it was found that animals with iron overload have an impaired microarchitecture of bones due to the compromised formation of the trabecular bone and a decreased number of trabeculae. This mechanism is probably the main cause of the harmful effect of iron on bones [22].

**Diabetes mellitus**

Decreased insulin secretion is considered the main cause of diabetes in HH patients, with insulin resistance playing the secondary role. Research suggests that bloodletting may delay the development of diabetes type 2 in patients diagnosed with HH. According to the recently published studies, 13-23% of patients with hereditary hemochromatosis suffer from diabetes, a rate much lower than several decades ago [23].

Dubois et al demonstrated that the frequency of the Cys282Tyr and His63Aps mutations of the HFE gene in patients with diabetes type 2 is higher in comparison to the general population. In another article, the same research team investigated whether diabetes type 2 constitutes sufficient evidence to suspect HH and suggested genetic screening only for patients with concomitant liver cirrhosis [24-25].

The strongest correlation between the presence of the HFE gene mutation and the incidence of diabetes type 2 was determined by Moczulski et al. In research conducted on a Polish population, the presence of the H63D mutation was found to be a risk factor for diabetic neuropathy, and the prevalence of the C282Y mutation was greater in patients with diabetes type 2 than in the general population [26].

The results of the Hemochromatosis and Iron Overload Screening (HEIRS) study published in 2006 are quite different: in a large group of patients (223 homozygotic carriers of the C282Y mutation and 449 controls; all with no previous history of diabetes), the percentage of patients with undiagnosed diabetes or an abnormal fasting blood glucose level was similar for C282Y homozygotes and the general population [25].

In a study published by Davis et al. in 2008, 1245 patients with diabetes type 2 were evaluated and no correlation was found between increased iron levels, the presence of the HFE gene mutation and diabetes type 2. Based on their results, screening for HH in patients with diabetes is not required [27].

In a meta-analysis of 23 studies conducted between 1997 and 2011, the prevalence of diabetes type 2 in carriers of the C282Y mutation, both homo- and heterozygotic, was comparable to the prevalence of diabetes in the general population. Carriers of the H63D mutation in the HFE gene had a slightly higher risk for developing diabetes type 2 [28].

**Conclusions**

Taking into consideration the latest research, it is not diabetes that seems to be the most common endocrinopathy in hemochromatosis, but hypogonadism – it does not only lower the quality of life, but may also lead to insidious and gradually progressive osteoporosis, fractures and progressing disability. Patients with HH should be monitored by both a hepatologist and endocrinologist, and a special emphasis should be put on the necessity of performing screening tests for decreased bone mineral density. The treatment should not be reduced only to decreasing the amount of iron in the organism, but it should also include vitamin D3 supplementation, gonadal hormone replacement therapy and the use of bisphosphonates.

**References**


